Mirae Asset Global Investments Co. Ltd. Reduces Stock Position in Seelos Therapeutics, Inc. (NASDAQ:SEEL)

Mirae Asset Global Investments Co. Ltd. lowered its holdings in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 66.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 303,714 shares of the company’s stock after selling 596,059 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 4.12% of Seelos Therapeutics worth $422,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Modera Wealth Management LLC boosted its holdings in Seelos Therapeutics by 40.4% during the 3rd quarter. Modera Wealth Management LLC now owns 1,223,776 shares of the company’s stock valued at $225,000 after acquiring an additional 352,271 shares during the period. Sabby Management LLC purchased a new position in Seelos Therapeutics during the 3rd quarter valued at $2,170,000. Gendell Jeffrey L boosted its holdings in Seelos Therapeutics by 30.5% during the 3rd quarter. Gendell Jeffrey L now owns 6,744,585 shares of the company’s stock valued at $1,241,000 after acquiring an additional 1,576,565 shares during the period. AdvisorShares Investments LLC boosted its holdings in Seelos Therapeutics by 110.5% during the 3rd quarter. AdvisorShares Investments LLC now owns 621,317 shares of the company’s stock valued at $114,000 after acquiring an additional 326,115 shares during the period. Finally, Stratos Wealth Advisors LLC purchased a new position in Seelos Therapeutics during the 3rd quarter valued at $53,000. Hedge funds and other institutional investors own 23.37% of the company’s stock.

Seelos Therapeutics Stock Performance

SEEL opened at $0.29 on Friday. The business has a fifty day moving average of $0.71 and a 200 day moving average of $2.02. Seelos Therapeutics, Inc. has a 52-week low of $0.28 and a 52-week high of $49.80.

Seelos Therapeutics Profile

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).